InspireMD, Inc. (NSPR) Q3 Revenue Falls 11.1% as Net Loss Narrows

Q3 2026 revenue fell 11.1% to $2.2M versus $2.5M a year earlier; net loss narrowed to $9.8M from $12.7M. InspireMD also received FDA approval for CGuard Prime in TCAR procedures, which it expects to approximately double its U.S. addressable market.Material DetailsContext by AI AnalystThis is a mixe…